Sign In
Last checked at 
10 Oct 2019 07:00
Diaceutics PLC
("Diaceutics" or the "Company")
Workshop presentation at EORTC
Diaceutics PLC (AIM: DXRX), the data analytics and implementation services company which services the global pharmaceutical industry, announces it will attend the EORTC (European Organisation for Research and Treatment of Cancer) Melanoma meeting in Florence on 10 October 2019. Dr. Marianna Sciortino, Director of the Global Laboratory Team at Diaceutics will participate in a workshop entitled "Emerging biomarkers in melanoma treatment: are we ready for the challenge?" Diaceutics have been invited to present by one of the top EU melanoma experts, Professor Daniela Massi.
Dr. Sciortino will discuss the current biomarkers necessary for identifying patients for treatment with currently available targeted therapies and new emerging biomarkers that could be important for future treatments. The Company will highlight the evidence surrounding the predictive role of PD-L1, TMB and NTRK biomarkers, discussing the challenges of how these markers are used in clinical practice.
The EORTC Melanoma group is one of the largest melanoma networks in the world, and conducts clinical trials and translational research in the melanoma field. Its objectives are to improve clinical care of patients suffering with cutaneous or ocular melanoma, and to increase knowledge about melanoma acquisition and progression.
Enquiries:
Diaceutics PLC | www.diaceutics.com | ||||
Peter Keeling, Chief Executive Officer | via Walbrook PR | ||||
Philip White, Chief Financial Officer | |||||
Cenkos Securities plc (Nominated adviser) | +44 (0) 20 3861 6630 | ||||
Callum Davidson / Giles Balleny | |||||
Walbrook PR | Tel: +44 (0)20 7933 8780 or diaceutics@walbrookpr.com | ||||
Anna Dunphy | Mob: +44 (0)7876 741 001 | ||||
Paul McManus | Mob: +44 (0)7980 541 893 | ||||
About Diaceutics
Diaceutics PLC is a leading diagnostics data analytics and implementation services provider for global pharmaceutical companies. The Company, quoted on the Alternative Investment Market (AIM) of the London Stock Exchange, is enabling Pharma to accelerate their market penetration and achieve a better return on precision medicine therapies by helping them to revolutionise patient testing. By generating insights from its data lake of clinical laboratory testing data and other data, Diaceutics helps Pharma understand and leverage the diagnostic landscape through initiatives that improve patient testing, leading to better treatment outcomes. The Company works with more than 30 global pharmaceutical companies across hundreds of precision medicine projects. The Company employs a leading global group of experts from the laboratory, diagnostic and pharmaceutical industries. www.diaceutics.com
Follow the stocks
